摘要
目的探讨糖尿病对医院获得性耐甲氧西林金黄色葡萄球菌(MRSA)肺炎的临床转归有无影响。方法回顾性分析116例MRSA引起的医院获得性肺炎患者,根据检测有无糖尿病,分为糖尿病组65例和对照组51例。评估两组给予利奈唑胺和万古霉素抗炎治疗后的临床转归。结果糖尿病组随机血糖、糖化血红蛋白与对照组比较,差异有统计学意义(P<0.05)。糖尿病组患者给予利奈唑胺治疗,临床治疗与痰液细菌学检测有效率高于万古霉素(P=0.045与P=0.029)。第30天的全因死亡率,糖尿病组患者高于对照组(16.9%与9.8%,P=0.040)。结论糖尿病可使医院获得性MRSA肺炎30天内的全因死亡率增加,给予利奈唑胺治疗的临床转归优于万古霉素。
Objective To investigate the effect of diabetes on clinical outcome of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus(MRSA).Methods A retrospective analysis of 116 patients with nosocomial pneumonia caused by MRSA was conducted in this study.They were divided into two groups depending on diabetes.The clinical outcomes of the two groups were evaluated after the treatment of linezolid and vancomycin.Results The blood glucose and glycated hemoglobin in the diabetic group were significantly higher than those in the control group(P<0.05).The effective rate of linezolid treatment in the diabetic group was higher than vancomycin(P=0.045 and P=0.029).The total mortality in 30 days was higher in the diabetic group than in the control group(16.9%and 9.8%,P=0.040).Conclusion The total mortality of nosocomial pneumonia caused by MRSA with diabetes increases in 30 days.The clinical outcome of linezolid is better than that of vancomycin.
作者
孟波
牛世坤
MENG Bo;NIU Shi-kun(Maternal and Child Health Care Hospital,Shiyan,Hubei 442000,China)
出处
《临床肺科杂志》
2018年第5期857-860,共4页
Journal of Clinical Pulmonary Medicine
